Source: Clinical Laboratory News
Roche has signed a definitive agreement to acquire all shares of Flatiron Health for $1.9 billion in a transaction that is expected to close in the first half of 2018. Flatiron is a healthcare technology and services company that specializes in oncology-specific electronic health record software, as well as the curation and development of real-world evidence for cancer research. Flatiron Health has worked closely with more than 265 community cancer clinics, six major academic research centers, and 14 therapeutic oncology companies to create a technology platform designed to enable researchers and care providers to learn from the experiences of individual cancer patients. “As a leading technology company in oncology, Flatiron Health is best positioned to provide the technology and data analytics infrastructure needed not only for Roche, but for oncology research and development efforts across the entire industry,” said Daniel O’Day, CEO of Roche Pharmaceuticals.